Region:
All editions →MethodologyUpdated · November 2026
P
eupeptideguide
Find my vendor →
Amylin analogue research

Cagrilintide.
1 vendor · €103

Long-acting amylin-receptor agonist (AM833 / NNC0174-0833) developed by Novo Nordisk, studied alone and in the CagriSema combination; not approved as a medicine anywhere and not for human therapeutic use.

Clinical-stageLyophilised vialAlso known as:AM833 · NNC0174-0833
Compound specification
Formula
C₁₉₄H₃₁₂N₅₄O₅₉S₂
CAS
1415456-99-3
Half-life
Long-acting — half-life in the order of a week in the Phase 1b study (Enebo et al. 2021); no label value exists
Storage
Lyophilised powder below −15 °C in a tightly closed container, shielded from light; equilibrate the sealed vial to room temperature before opening. Reconstituted vials 2–8 °C.
Sizes
5 mg, 10 mg, 20 mg
What it is

The compound. Origin, research and regulatory reality.

Cagrilintide (development codes AM833 and NNC0174-0833) is a synthetic long-acting amylin analogue developed by Novo Nordisk, engineered from the amylin sequence with a fatty-diacid side chain that gives it a long, once-weekly-compatible half-life. It is also formulated with semaglutide as the investigational fixed-dose combination CagriSema.

A Phase 1b study (Enebo et al., 2021) characterised its pharmacokinetics alongside semaglutide, and a Phase 2 trial (Lau et al., 2021) examined once-weekly cagrilintide monotherapy in adults with overweight or obesity. The Phase 3 REDEFINE programme (Garvey et al., 2025) studied the CagriSema combination against each component alone.

Novo Nordisk submitted CagriSema to the FDA for weight management in December 2025; as of September 2026 neither cagrilintide alone nor CagriSema is an approved medicine in any jurisdiction. The FDA states that cagrilintide cannot be used in compounding under federal law and is not a component of any FDA-approved drug. Research-use-only vials sold commercially are outside Novo Nordisk’s clinical-trial supply chain and have not been reviewed for safety, effectiveness or quality.

Live vendor register · grouped by strength

Every vendor. Cheapest per mg first, kits listed separately.

CAGRILINTIDE · price per mg
1 listing · unflagged vendors first · Listings data last updated October 2026

Best price per mg: Adria Science 10 mg at €10.30/mg.

10 mg

1 listing
01
Adria ScienceVID-ADRIA-SC · SI/CZ dispatch
10 mg
99.1%
Liquilabs per-lot COA
Low stock
Dispatch 1–3 days
€10.30/mg
€103
Go →
Representative literature

Research context. Recent peer-reviewed work.

2021 · Lancet
Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial
cited by n = 96DOI ↗
2021 · Lancet
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
cited by n = 706DOI ↗
2025 · N. Engl. J. Med.
Coadministered cagrilintide and semaglutide in adults with overweight or obesity (REDEFINE 1)
DOI ↗
Common questions

Frequently asked.

Is cagrilintide legal to buy?

It is not an approved medicine anywhere and the FDA states it cannot be used in compounding under federal law. Products sold research-use-only are for laboratory research, not human use; RUO labelling does not authorise personal use.

How is research-vial cagrilintide different from CagriSema?

CagriSema (cagrilintide plus semaglutide) is an investigational combination submitted to the FDA, not an approved pharmacy product. Any cagrilintide vial sold commercially is outside Novo Nordisk’s controlled clinical-trial supply chain.

What should a CoA show for cagrilintide?

HPLC purity, LC-MS mass confirmation against the PubChem-listed formula C194H312N54O59S2, a lot number, an independent third-party lab name and a test date. Published molecular-weight figures vary by source, so check the measured mass rather than a stated weight.

Same research area

Similar compounds.

GH secretagogue research

Ipamorelin

Synthetic pentapeptide described in 1998 by Novo Nordisk researchers as a selective ghrelin/GH-secretagogue receptor agonist; researched for growth-hormone release. Not approved for human therapeutic use.
7 vendors€14–45
GHRH analogue research

CJC-1295

GHRH(1-29) analogue developed by ConjuChem; the DAC form binds albumin and persists for days, the no-DAC form (Mod GRF 1-29) is short-acting. Researched for GH/IGF-1 stimulation; not approved for human therapeutic use.
7 vendors€22–89
Fat metabolism research fragment

AOD-9604

Modified C-terminal fragment of human growth hormone (hGH 177–191). Researched for adipose-tissue mechanisms; not approved for human therapeutic use.
5 vendors€21–60
Triple hormone agonist research

Retatrutide

Investigational triple GIP/GLP-1/glucagon receptor agonist (LY3437943) developed by Eli Lilly and studied in Phase 3 trials; not approved as a medicine anywhere and not for human therapeutic use.
5 vendors€70–122
GIP/GLP-1 dual agonist research

Tirzepatide

Dual GIP/GLP-1 receptor agonist, FDA- and EMA-approved as Mounjaro and Zepbound. Research-vial tirzepatide is a different, unapproved product, not made or reviewed as those medicines, and not for human use.
3 vendors€40–90
Long-form research guide

Weight Loss Research. Mechanism + protocols + safety.

Lipolysis, GH secretagogues, and adipose tissue modulation in obesity models

Open the long-form guide for Cagrilintide →